Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-09-26-Speech-1-035-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110926.16.1-035-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"World-class research funding needs to occur within a broader EU policy framework that supports economic growth and increases our global competitiveness. All too often, companies refer to conflicting policies in the EU. Last week I visited GE Healthcare in Wales where they research and commercialise state-of-the-art stem cell lines for pharmaceutical testing. The use of
cell lines will provide a valuable alternative to animal testing but needs all 27 Member States to adopt a common set of rules for their use.
I was also visited last week by the Cord Blood Association, which supports key EU research but believes that policies could be better coordinated so that a European depositary might be a reality in the future for medical research samples to rival the NIH in the US.
A single set of rules would assist our research competitiveness, and interaction between leading industrial players in Europe and our academic institutions should be the norm as we pursue a competitive agenda.
For our research and innovation to be world class it must remain competitive and withstand at all times peer review."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples